Your browser doesn't support javascript.
loading
The ixabepilone and vandetanib combination shows synergistic activity in docetaxel-resistant MDA-MB-231 breast cancer cells.
Tam, Stanton; Al-Zubaidi, Yassir; Rahman, Md Khalilur; Bourget, Kirsi; Zhou, Fanfan; Murray, Michael.
Afiliación
  • Tam S; Pharmacogenomics and Drug Development Group, Discipline of Pharmacology, School of Medical Sciences, University of Sydney, New South Wales, 2006, Australia.
  • Al-Zubaidi Y; Pharmacogenomics and Drug Development Group, Discipline of Pharmacology, School of Medical Sciences, University of Sydney, New South Wales, 2006, Australia.
  • Rahman MK; College of Pharmacy, The University of Mashreq, Baghdad, Iraq.
  • Bourget K; Pharmacogenomics and Drug Development Group, Discipline of Pharmacology, School of Medical Sciences, University of Sydney, New South Wales, 2006, Australia.
  • Zhou F; Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, New South Wales, 2006, Australia.
  • Murray M; Pharmacogenomics and Drug Development Group, Discipline of Pharmacology, School of Medical Sciences, University of Sydney, New South Wales, 2006, Australia.
Pharmacol Rep ; 74(5): 998-1010, 2022 Oct.
Article en En | MEDLINE | ID: mdl-35908023

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Triple Negativas / Antineoplásicos Límite: Humans Idioma: En Revista: Pharmacol Rep Asunto de la revista: FARMACOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Triple Negativas / Antineoplásicos Límite: Humans Idioma: En Revista: Pharmacol Rep Asunto de la revista: FARMACOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Suiza